Actelion
Actelion
€2,825.10
Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Description
Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Highlights
Strategic insight into the prospects for Actelion over the next 10 years. Datamonitor Healthcare identifies key strengths, weaknesses, opportunities, and threats, and evaluates the company’s prescription pharmaceuticals outlook using a variety of cuts of historical and forecast sales data.
Methodology
The prescription pharmaceutical outlook of Actelion is derived from Datamonitor Healthcare’s own in-house sales-based forecasting models, with all historical product sales originating from company-reported information.
Table of Contents
EXECUTIVE SUMMARY 4
COMPANY CONTEXT 5
Actelion 5
Defense against generic erosion of Tracleer a priority 5
Follow-on products in pulmonary arterial hypertension 5
Diversification 5
Bibliography 7
FACTS AND FIGURES 8
Actelion’s prescription pharma sales outlook 8
Actelion’s top 10 products over 2015–25 8
Actelion’s growth drivers and resistors 9
Actelion’s top 10 products over 2015–25 10
Actelion’s launch/core/expiry analysis 11
Actelion’s financial outlook 12
Actelion’s M&A history 13
Actelion’s key catalysts 13
KEY THERAPY AREAS 14
Cardiovascular 14
Actelion’s aims to maintain its leadership in PAH through the expansion of follow-on Opsumit 14
Opsumit’s strong clinical profile is reflected in its label 15
Actelion’s novel prostacyclin analog Uptravi will build on the company’s leadership in PAH 15
Bibliography 17
Figure 2: Actelion’s prescription pharmaceutical sales ($m) and growth rate (%), 2012-2025
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Turkey Regulatory Issues 
Sign up to the